Adverse effects associated with the intrathecal administration of ziconotide
Adverse effects associated with the intrathecal administration of ziconotide
复制标题
DOI：
10.1016/s0304-3959(99)00254-7
复制
发表时间：
2000-03-01
期刊：
影响因子：
7.4
通讯作者：
Paice, JA
中科院分区：
文献类型：
--
作者：
Penn, RD;Paice, JA
ω-芋螺肽齐考诺肽是一种N-型钙通道阻滞剂，已被证明在动物中使用福尔马林和热板试验产生抗伤害感受。最初的报告显示，在阿片类药物不能缓解疼痛的癌症和艾滋病患者中鞘内注射齐考诺肽具有镇痛疗效。尽管报告了不良反应，但似乎可以通过减少剂量或对症治疗轻松管理。本临床报告描述了3例鞘内注射齐考诺肽相关严重不良反应患者的经验。(C)2000年国际疼痛研究协会。由Elsevier Science B. V.出版，保留所有权利。
The w-conopeptide, ziconotide, is an N-type calcium-channel blocker that has been shown to produce antinociception in animals using formalin and hot-plate tests. Initial reports of intrathecal administration of ziconotide in cancer and AIDS patients whose pain was unrelieved with opioids demonstrated analgesic efficacy. Although adverse effects were reported, these appeared to be easily managed through dose reduction or symptomatic treatment. This clinical report describes the experiences of three patients with serious adverse effects associated with intrathecal ziconotide. (C) 2000 International Association for the Study of Pain. Published by Elsevier Science B.V. AII rights reserved.